Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of BNT327 plus etoposide/carboplatin versus atezolizumab plus etoposide/carboplatin in first-line extensive-stage small cell lung cancer
CTR20251195Phase 3Active
- Sponsor
- Biotheus
- Start
- May 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pumitamig, atezolizumab, etoposide, carboplatin in small cell lung cancer (SCLC), sponsored by Biotheus. Started May 2025; status: active.
02
Drugs
pumitamigatezolizumabetoposidecarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20251195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251195.